Updates are available Correction dated 2022-12-06

Article History

Received: 11 January 2022

Revised: 25 April 2022

Accepted: 6 May 2022

First Online: 2 June 2022

Change Date: 6 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00417-022-05917-x

Declarations

:

: This surveillance was conducted in compliance with the Good Post-marketing Study Practice (GPSP) and Good Vigilance Practice (GVP) of the Ministry of Health, Labor, and Welfare in Japan. Approval by the ethics committee of each institution was not mandatory, since GPSP and GVP do not require such approval for a post-marketing surveillance. The need for informed consent was waived.

: Not applicable due to the above reasons.

: MS received research funding form Novartis, Chugai, Alcon, and Bayer; personal fees or support from Novartis, Alcon, Santen, Kowa, Senju, Bayer, and Wakamoto outside the submitted work. MK received research funding from Novartis, Alcon, Santen, Otsuka, Senju, HOYA, Pfizer, AMO, and Polish; consulting fees from Senju and Ono; personal fees or support from Novartis, Alcon, Santen, Sanofi, Kowa, Otsuka, Senju, Nidek, Bayer, Ono, Sanwa Kagaku, and Chuo Sangyo Boeki outside the submitted work. Although MK is an editorial board member of the journal, there was no involvement with the peer review process for this article. CH, KH, and TS are employees of Bayer Yakuhin, Ltd.